New blood test could boost IVF success for women with repeated failure
NCT ID NCT07363018
First seen Jan 28, 2026 · Last updated Jun 23, 2026 · Updated 19 times
Summary
This study tests whether a simple blood test measuring miRNA levels can predict the best time to transfer an embryo during IVF. About 546 women with unexplained recurrent implantation failure will be randomly assigned to either standard embryo transfer or transfer timed based on the blood test results. The goal is to see if personalized timing improves pregnancy rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT IMPLANTATION FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
peripheral blood miRNA analysis
What this could lead to
If successful, this blood test could help doctors time embryo transfers more precisely, potentially increasing pregnancy rates for women with recurrent implantation failure.
What could go wrong
This is an early-stage trial with no prior proof of benefit. The test may not improve outcomes, and results may not apply to all patients.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.